+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Investigation of drug-receptor interactions by means of irreversible receptor inhibitors: binding of oxytocin and angiotensin II to their receptors in rat uterus



Investigation of drug-receptor interactions by means of irreversible receptor inhibitors: binding of oxytocin and angiotensin II to their receptors in rat uterus



Journal of Receptor Research 4(1-6): 371-383



A stimulus-response coupling model in which individual steps follow hyperbolic or Hill-type laws has been employed to mimic phenomena associated with irreversible receptor inhibition (receptor reserve) in a responding biological system. Two methods for computation of ligand-receptor dissociation constant (KA) have been derived from this model: 1) The relation between pD2 and maximal attainable response allows a rough estimate of KA; 2) A generalization of the earlier Furchgott-Bursztyn procedure employing equipotent doses for noninhibited and partially inhibited systems, has been achieved by introduction of Hill equation into the model. Applied to oxytocin and angiotensin II receptors in rat uterus, these pharmacological methods indicate rather low affinity of the two receptors for the respective peptides (around 2 X 10(-8) for angiotensin II and 2 X 10(-7) mol/l for oxytocin), in case of oxytocin much lower than values reported from binding studies. Apparently, several binding sites are present on the target tissue cells from which the methods based on cellular response can pick up those corresponding to the receptors. Biophysical methods are lacking this ability. Single pD2 values in noninhibited systems cannot themselves deliver any relevant information about receptor binding.

(PDF emailed within 0-6 h: $19.90)

Accession: 043462839

Download citation: RISBibTeXText

PMID: 6098663

DOI: 10.3109/10799898409042562


Related references

Structural requirements of the oxytocin receptor in rat uterus. Free-Wilson analysis in a series of competitive oxytocin inhibitors. International Journal of Peptide and Protein Research 31(6): 520-536, 1988

Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. European Journal of Pharmacology 510(1-2): 9-16, 2005

Vasopressin, angiotensin and adrenergic receptors of rat liver Golgi fractions--molecular weight of the angiotensin-receptor irreversible complex after in vitro and in vivo labelling. Molecular and Cellular Endocrinology 51(1-2): 59-69, 1987

Vasopressin, angiotensin and adrenergic receptors of rat liver Golgi fractions Molecular weight of the angiotensin-receptor irreversible complex after in vitro and in vivo labelling. Molecular and Cellular Endocrinology 51(1): 59-69, 1987

Monoclonal antibodies to oxytocin as possible inhibitors of oxytocin binding to its receptor. American Journal of Obstetrics & Gynecology 184(1): S47, 2001

Comparison of binding of oxytocin and an oxytocin antagonist nu 8702 to oxytocin receptors in the pregnant rat uterus. Biology of Reproduction 40(SUPPL 1): 71, 1989

Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors. Primary Care 41(4): 765-778, 2015

Differential regulation of estrogen receptor alpha and beta mRNAs in the rat uterus during pregnancy and labor: possible involvement of estrogen receptors in oxytocin receptor regulation. Endocrine Journal 50(5): 579-587, 2003

Oxytocin receptors and parturition 3. increases in estrogen receptor and oxytocin receptor concentrations in the rat myometrium during prostaglandin f 2 alpha induced abortion. Endocrinology 106(3): 739-743, 1980

Progress in the understanding of drug-receptor interactions, Part 1: experimental charge-density study of an angiotensin II receptor antagonist (C30H30N6O3S) at T = 17 K. Chemistry 11(16): 4621-4634, 2005

Characterization and localization of oxytocin receptors in the uterus and oviduct of the non-pregnant ewe using an iodinated receptor antagonist. Journal of Endocrinology 128(2): 187-195, 1991

Quantitative aspects of drug-receptor interactions. I. Ca2+ and cholinergic receptor activation in smooth muscle: a basic model for drug-receptor interactions. Journal of Theoretical Biology 40(1): 125-154, 1973

Angiotensin-(1-7) Suppresses Hepatocellular Carcinoma Growth and Angiogenesis via Complex Interactions of Angiotensin II Type 1 Receptor, Angiotensin II Type 2 Receptor and Mas Receptor. Molecular Medicine 21: 626-636, 2016

Drug delivery to the human and mouse uterus using immunoliposomes targeted to the oxytocin receptor. American Journal of Obstetrics and Gynecology 216(3): 283.E1-283.E14, 2016

Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: thermodynamics of cytoplasmic steroid/nuclear receptors in comparison with membrane receptors. Journal of Medicinal Chemistry 48(6): 2026-2035, 2005